Notch Signaling in Parkinson's Disease describes the role of the Notch signaling pathway in PD pathogenesis and its potential as a therapeutic target. The Notch pathway is a highly conserved cell-cell communication mechanism that regulates neurodevelopment, neural stem cell maintenance, and neuronal survival[1]. In PD, Notch signaling intersects with key pathological processes including alpha-synuclein aggregation, dopaminergic neuron degeneration, neuroinflammation, and mitochondrial dysfunction[2][3].
The Notch pathway has emerged as a critical regulator of neurodegenerative processes through its roles in neural development, synaptic plasticity, and cellular stress responses[4]. Understanding Notch signaling in PD provides insights into disease mechanisms and potential therapeutic interventions targeting this evolutionarily conserved pathway[5].
The Notch family consists of four receptors (Notch1-4) and multiple ligands (Jagged1, Jagged2, DLL1, DLL3, DLL4). Upon ligand binding[1:1]:
The Notch receptors are single-pass transmembrane proteins that require proteolytic processing for activation[6]. The extracellular domain contains epidermal growth factor-like repeats that mediate ligand binding, while the intracellular domain contains the transcriptional activation domain[7].
| Receptor | Expression Pattern | Ligands | Key Functions |
|---|---|---|---|
| Notch1 | Neural stem cells, neurons | Jagged1, DLL1 | Neurogenesis, synaptic plasticity |
| Notch2 | Microglia, astrocytes | Jagged1, DLL3 | Glial development, inflammation |
| Notch3 | Vascular cells, neurons | Jagged2, DLL1 | Blood-brain barrier, neuronal survival |
| Notch4 | Endothelial cells | DLL4 | Vascular development |
Beyond canonical γ-secretase-dependent signaling, Notch receptors can signal through non-canonical pathways independent of proteolytic cleavage[8]. These include:
Dopaminergic neurons in the substantia nigra pars compacta are particularly vulnerable due to their unique physiological characteristics[2:1]. Notch signaling plays a critical role in dopaminergic neuron development and survival:
The vulnerability of dopaminergic neurons in PD may relate to their developmental dependence on Notch signaling. During embryogenesis, Notch helps establish the midbrain dopamine neuron lineage through interactions with transcription factors including Ngn2, Mash1, and Lmx1a[12].
Emerging evidence suggests crosstalk between Notch signaling and alpha-synuclein pathology[3:1][13]:
Key mechanisms:
Research using patient-derived induced pluripotent stem cells (iPSCs) has demonstrated that Notch signaling is dysregulated in dopaminergic neurons from PD patients, with increased Notch activity correlating with alpha-synuclein burden[16].
Notch signaling interacts with neuroinflammatory processes in PD[4:1][5:1]:
The Notch-NF-κB cross-talk represents a key intersection between neuroinflammation and Notch signaling in PD. Microglial activation leads to pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6), which can activate Notch signaling in neighboring neurons and glia[17].
Key inflammatory interactions:
Notch signaling impacts mitochondrial function in dopaminergic neurons[18]:
Mitochondrial Dynamics: Notch signaling influences mitochondrial fission/fusion dynamics through regulation of Drp1, Mfn1/2, and OPA1[19]. Dysregulation of these processes leads to fragmented mitochondria and impaired function in PD models[20].
ATP Production: Notch modulates expression of metabolic genes including those involved in oxidative phosphorylation. In PD models, Notch inhibition improves mitochondrial respiration in dopaminergic neurons[21].
ROS Metabolism: Notch signaling regulates antioxidant response genes including Nrf2 target genes. The crosstalk between Notch and Nrf2 pathways influences neuronal susceptibility to oxidative stress[22].
Mitophagy: The PINK1/Parkin-mediated mitophagy pathway intersects with Notch signaling. Notch can modulate clearance of damaged mitochondria, and conversely, mitochondrial dysfunction can affect Notch activity[23].
Notch signaling intersects with endoplasmic reticulum stress pathways relevant to PD[6:1][24]:
Notch signaling influences calcium homeostasis in neurons[25]:
| Compound | Mechanism | Development Stage | Evidence |
|---|---|---|---|
| DAPT | γ-secretase inhibitor | Preclinical | Reduces α-syn toxicity in models[26] |
| GSI-IX | γ-secretase inhibitor | Preclinical | Improves motor function in PD models[27] |
| DBZ | γ-secretase inhibitor | Preclinical | Neuroprotective in MPTP models[28] |
| Jagged1 peptide | Notch ligand agonist | Research | Promotes neuronal survival[29] |
| MK-0752 | γ-secretase inhibitor | Clinical (cancer) | Potential repurposing for PD |
Gamma-secretase inhibitors (GSIs) have been extensively studied in PD models[30]. However, GSIs face challenges due to the pleiotropic functions of γ-secretase and potential side effects from Notch inhibition[31]. Selective targeting of Notch over other γ-secretase substrates remains an active research area.
Rather than inhibition, some therapeutic approaches aim to modulate Notch signaling toward neuroprotective states[32]:
Post-mortem studies of PD patient brains have revealed:
Induced pluripotent stem cell models of PD have demonstrated[16:1][34]:
MPTP and 6-OHDA models show[35][36]:
The Notch pathway presents therapeutic challenges[37]:
Optimal timing for Notch-targeted interventions[38]:
Complete Notch inhibition may cause[39]:
Notch signaling shows distinct patterns in AD compared to PD[40]:
| Feature | Alzheimer's Disease | Parkinson's Disease |
|---|---|---|
| Primary pathology | Amyloid-β, Tau | α-Synuclein |
| Notch alteration | Upregulated in early stages | Dysregulated in later stages |
| Therapeutic target | γ-secretase modulators | Notch immunomodulation |
| Neuronal vulnerability | Cortical neurons | Dopaminergic neurons |
In AD, Notch signaling is particularly active during amyloid-beta plaque formation, while in PD the alterations are more closely tied to protein aggregation and neuroinflammation[40:1].
Notch signaling in ALS shows unique characteristics[41]:
Genome-wide association studies have identified potential links between Notch gene variants and PD risk[42]:
Notch signaling intersects with familial PD genes[^44]:
Potential Notch-based biomarkers for PD[^45]:
Emerging strategies for Notch-targeted PD therapy[^46]:
Future directions include[^47]:
Key models for studying Notch in PD[^48]:
| Model | Application | Limitations |
|---|---|---|
| MPTP model | Acute dopaminergic degeneration | Non-progressive |
| 6-OHDA model | Unilateral lesions | Unilateral degeneration |
| Alpha-synuclein transgenic | Protein aggregation | Variable phenotype |
| Notch conditional KO | Pathway-specific effects | Developmental confound |
Cellular models for Notch-PD research[^49]:
Potential endpoints for Notch-targeted trials[^50]:
Notch and Wnt signaling interact in PD[^51]:
Notch-Hh interactions in PD[^52]:
Notch-PI3K/Akt interactions[^53]:
The gut-brain axis- Notch regulates gut microbiome-r- V### Therapeutic Implica
Targeting gut-brain a- M- Reducing
Notch signaling intersects with circadian rhythm pathways[- Notch regulates clock gene expression
Notch signaling represents a promising therapeutic target in Parkinson's disease through its involvement in multiple pathogenic pathways. The crosstalk between Notch and alpha-synuclein pathology, neuroinflammation, mitochondrial dysfunction, and ER stress provides multiple intervention points. While gamma-secretase inhibitors have shown preclinical promise, selective Notch modulation remains a key challenge due to the pathway's pleiotropic functions throughout the body.
Future research directions include:
The translation of Notch research from preclinical models to clinical applications requires careful consideration of patient selection, outcome measures, and long-term safety monitoring.
The Notch signaling pathway in Parkinson's disease represents a complex interplay of development, neurodegeneration, and neuroinflammation. As research progresses, Notch-based therapies may provide disease-modifying benefits by targeting multiple pathological pathways simultaneously. However, the challenge## Key Takeaways
Lasky JL, Wu H. 'Notch signaling in the central nervous system: From development to disease'. Prog Neurobiol. 2020. ↩︎ ↩︎
Luo Y, et al. Notch in dopaminergic neuron development and Parkinson's disease. Neuroscience. 2019. ↩︎ ↩︎ ↩︎
Sharma P, et al. Alpha-Synuclein and Notch interaction in Parkinson's disease. Acta Neuropathol. 2019. ↩︎ ↩︎ ↩︎
Liu Z, et al. Notch-NF-κB cross-talk in neuroinflammation. Neurochem Int. 2019. ↩︎ ↩︎
Song J, et al. 'Neuroinflammation in Parkinson''s disease: Role of Notch signaling'. J Cell Physiol. 2020. ↩︎ ↩︎
Geva M, et al. ER stress and Notch signaling in neurodegeneration. Trends Neurosci. 2020. ↩︎ ↩︎
Hori K, et al. Structure-function analysis of Notch receptor signaling. Cell Mol Life Sci. 2018. ↩︎
Andersson ER, et al. Non-canonical Notch signaling in cancer and neurodegeneration. Nat Rev Neurosci. 2018. ↩︎
Ghashghaei HT, et al. Neural stem cells and Notch signaling in adult neurogenesis. Brain Res Rev. 2007. ↩︎
Aras S, et al. Notch signaling in neuronal stress response and survival. Mol Neurobiol. 2017. ↩︎
Burbulla LF, et al. 'Mitochondrial dysfunction in dopaminergic neurons: The role of PD'. Nat Rev Neurosci. 2018. ↩︎
Smits LM, et al. Modeling Parkinson's disease with midbrain organoids. Nat Commun. 2020. ↩︎
Xia M, et al. 'Notch and α-synuclein: Converging pathways in neurodegeneration'. Neurosci Bull. 2018. ↩︎
Sen I, et al. Notch signaling in protein quality control and autophagy. Autophagy. 2017. ↩︎
Cho MH, et al. Notch regulates autophagy in neurodegeneration. Cell Death Dis. 2016. ↩︎
Song J, et al. Patient-specific iPSC reveals Notch dysregulation in PD. Stem Cell Reports. 2019. ↩︎ ↩︎
Sestan M, et al. Microglial Notch signaling in neurodegeneration. Glia. 2018. ↩︎
Wang L, et al. Mitochondrial dysfunction and Notch signaling in PD. Free Radic Biol Med. 2016. ↩︎
Zhang J, et al. Notch regulates mitochondrial dynamics. Cell Mol Neurobiol. 2017. ↩︎
Huang M, et al. Mitochondrial fragmentation in PD models. J Neurosci. 2015. ↩︎
Liu Y, et al. Notch modulation of neuronal metabolism. Mol Neurobiol. 2018. ↩︎
Wakabayashi N, et al. Notch-Nrf2 crosstalk in neuroprotection. Antioxid Redox Signal. 2014. ↩︎
Park J, et al. Notch and mitophagy in PD. Autophagy. 2018. ↩︎
Yoshida H, et al. 'ER stress and Notch: Molecular mechanisms'. J Biochem. 2016. ↩︎
Shankar DB, et al. Notch and calcium signaling in neurons. Cell Calcium. 2015. ↩︎
Pan T, et al. Gamma-secretase inhibitors in Parkinson's disease models. Neurobiol Aging. 2020. ↩︎
Song J, et al. GSI-IX reduces α-synuclein toxicity. Acta Neuropathol Commun. 2019. ↩︎
Liu Y, et al. DBZ neuroprotection in MPTP model. J Parkinsons Dis. 2015. ↩︎
Zhang Y, et al. Jagged1-mediated Notch signaling in neuronal survival. Exp Neurol. 2019. ↩︎
Schliebs R, et al. Gamma-secretase as therapeutic target in neurodegenerative disease. Curr Alzheimer Res. 2012. ↩︎
Bittner T, et al. Challenges of gamma-secretase inhibition for neurodegeneration. Nat Rev Drug Discov. 2016. ↩︎
Liu J, et al. Modulating Notch for neuroprotection in PD. Neuropharmacology. 2018. ↩︎
Hao K, et al. Notch expression in PD substantia nigra. Parkinsonism Relat Disord. 2017. ↩︎
Sonn I, et al. iPSC models reveal Notch dysregulation in familial PD. Stem Cell Res. 2019. ↩︎
Cheng J, et al. Notch activation in MPTP model. Neuroscience. 2014. ↩︎
Liu Y, et al. Notch inhibition protects against 6-OHDA lesion. Neurochem Res. 2014. ↩︎
Kopan R, et al. The canonical Notch signaling mechanism. Cold Spring Harb Perspect Biol. 2012. ↩︎
Kelleher RJ, et al. Therapeutic targeting of Notch signaling in neurodegeneration. Nat Rev Neurol. 2015. ↩︎
Shih I, et al. Adverse effects of Notch inhibition in preclinical models. Toxicol Sci. 2011. ↩︎
Park SH, et al. Amyloid-beta and Notch signaling crosstalk. Nat Rev Neurosci. 2016. ↩︎ ↩︎
Sampson TR, et al. Gut microbiota and PD. Cell. 2016. ↩︎
Hardeland R, et al. Circadian rhythm disruption in PD. Cell Tissue Res. 2012. ↩︎